Artisan Partners Limited Partnership raised its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 0.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 307,062 shares of the biopharmaceutical company’s stock after buying an additional 743 shares during the period. Artisan Partners Limited Partnership’s holdings in Celgene Corporation were worth $39,878,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in CELG. CIBC World Markets Inc. boosted its position in shares of Celgene Corporation by 27.5% in the first quarter. CIBC World Markets Inc. now owns 105,626 shares of the biopharmaceutical company’s stock worth $13,143,000 after purchasing an additional 22,764 shares during the period. Holderness Investments Co. bought a new position in shares of Celgene Corporation in the first quarter worth approximately $205,000. State of Wisconsin Investment Board boosted its position in shares of Celgene Corporation by 34.8% in the first quarter. State of Wisconsin Investment Board now owns 877,713 shares of the biopharmaceutical company’s stock worth $109,214,000 after purchasing an additional 226,637 shares during the period. United Bank boosted its position in shares of Celgene Corporation by 35.9% during the first quarter. United Bank now owns 4,793 shares of the biopharmaceutical company’s stock worth $596,000 after acquiring an additional 1,267 shares during the last quarter. Finally, Mutual of America Capital Management LLC boosted its position in shares of Celgene Corporation by 1.4% during the first quarter. Mutual of America Capital Management LLC now owns 94,184 shares of the biopharmaceutical company’s stock worth $11,719,000 after acquiring an additional 1,334 shares during the last quarter. 79.48% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently weighed in on the stock. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $175.00 target price (up previously from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research report on Friday, October 20th. BMO Capital Markets reiterated an “outperform” rating and set a $160.00 price objective (up previously from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Finally, Leerink Swann reiterated a “buy” rating and set a $156.00 price objective on shares of Celgene Corporation in a research report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $139.57.

In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Insiders have sold a total of 20,227 shares of company stock valued at $2,843,956 over the last three months. 0.95% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Artisan Partners Limited Partnership Grows Stake in Celgene Corporation (CELG)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/artisan-partners-limited-partnership-grows-stake-in-celgene-corporation-celg/1721002.html.

Shares of Celgene Corporation (CELG) opened at $105.16 on Thursday. The firm has a market cap of $82,274.63, a PE ratio of 16.33, a PEG ratio of 0.81 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. Celgene Corporation’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the business earned $1.58 EPS. sell-side analysts predict that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.